The Marcus Foundation has awarded $28.7 million to Chuck Murry, MD, PhD, director of the USC Stem Cell Center, to support a clinical trial testing a stem cell-based therapy intended to regenerate heart muscle damaged by a severe heart attack. The award, the largest the foundation has given to the University of Southern California and one of its largest contributions to academic medicine, will fund both the planned human study and a parallel research program examining how the immune system responds to transplanted cardiac cells.

The trial is scheduled to begin in 2027 at Keck Hospital of USC in partnership with the USC Cardiac and Vascular Institute. A second clinical site will be established at the University of Washington, where elements of the technology were originally developed. The first phase will enroll approximately 18 patients who have experienced extensive myocardial infarction, the medical term for a heart attack that destroys part of the heart’s muscular wall.

Patients in the study will receive stem-cell-derived heart muscle cells delivered into regions damaged by the infarction. The primary goals will be to evaluate safety and determine whether the procedure is feasible in people with severe cardiac injury. Investigators will also monitor early biological signals, including whether the transplanted cells remain active, integrate with the injured tissue and produce measurable changes in cardiac performance during recovery and long-term follow-up.

A heart attack occurs when blood flow through a coronary artery is blocked, depriving cardiac muscle of oxygen. Within minutes, cells in the affected region begin to die, and the resulting scar tissue lacks the contractile properties of healthy myocardium. Unlike tissues such as skin or blood, adult human heart muscle has only a limited capacity for self-repair. As a result, a large infarction can weaken the heart’s pumping function, increase the risk of heart failure and leave survivors unable to perform ordinary activities without fatigue or breathlessness.

Current cardiovascular treatments can reopen blocked arteries, limit further injury and help the remaining heart muscle work more efficiently. They cannot, however, routinely replace the cardiomyocytes that have already been lost. Murry’s research program is aimed at addressing that biological gap by producing replacement heart muscle cells in the laboratory and delivering them directly to damaged tissue. The strategy represents a shift from supporting a failing heart to attempting to rebuild part of its contractile apparatus.

The transplanted cells are being developed as a form of cellular therapy, in which living cells act as the therapeutic agent rather than serving merely as a vehicle for a drug. According to Murry, the cells are intended to become active within the injured heart, contribute to repair and synchronize with surrounding muscle. Achieving that outcome requires more than placing new cells into scarred tissue: the cells must survive, connect functionally with the host myocardium and avoid creating dangerous electrical disturbances or abnormal rhythms. The initial trial is therefore designed principally to establish safety before testing therapeutic effectiveness in larger patient groups.

The foundation’s funding will also support research into the immune response triggered by cell transplantation. Even cells created from stem cells can be recognized as foreign by the recipient’s immune system, potentially leading to inflammation or destruction of the transplanted population. Patients who receive cellular grafts may consequently require immunosuppressive drugs, which can increase susceptibility to infection and produce other long-term complications. Researchers will study how immune cells interact with the implanted cardiac cells and investigate methods that could reduce or eventually eliminate the need for chronic immunosuppression.

The work builds on approximately three decades of research by Murry and his collaborators to move regenerative cardiology from laboratory experiments toward clinical treatment. The program includes gene-edited cellular technology, intended to improve the compatibility or performance of therapeutic cells in the human body. The precise effectiveness of the approach will not be known until it is tested in patients, and the small 2027 cohort will not be large enough to determine whether the therapy improves survival or prevents heart failure. Those questions would require subsequent trials involving substantially more participants and longer observation.

The Marcus Foundation described the project as a potential turning point for regenerative medicine, while USC leaders said the investment could create a platform for developing additional cellular therapies. The immediate scientific challenge is to determine whether transplanted heart muscle cells can be delivered safely and function meaningfully within severely damaged human hearts. If the trial meets its safety and feasibility objectives, it could provide the clinical evidence needed to advance a new generation of treatments for myocardial infarction—therapies designed not only to help patients live with damaged cardiac tissue, but to restore some of the function that conventional medicine cannot yet replace.

Subject of Research: Stem cell-based regenerative therapy for heart muscle damaged by myocardial infarction

Article Title: $28.7 Million Award Supports USC Trial of Stem Cell Therapy to Regenerate Heart Muscle After Heart Attack

Web References: The Marcus Foundation: https://marcusfoundation.org/; USC Stem Cell Center: https://stemcell.keck.usc.edu/; Chuck Murry Lab: https://murrylab.usc.edu/charles-chuck-murry-md-phd/; USC Cardiac and Vascular Institute: https://www.keckmedicine.org/services/cardiovascular/; Keck School of Medicine of USC: https://keck.usc.edu/

Image Credits: Steve Cohn

Keywords: Heart disease, myocardial infarction, heart attack, heart muscle, stem cell research, stem cell therapy, cell therapy, regenerative medicine, cardiovascular disorders, heart failure, clinical trial, cardiac regeneration

A new study finds plantations respond strongly to carbon dioxide, especially while young.

A groundbreaking imaging technology developed by researchers at the University of Oklahoma promises to revolutionize liver transplant evaluations by enabling more comprehensive and rapid assessments of donor organ health. With thousands of patients awaiting liver transplants nationwide, transplant teams urgently need tools that can deliver swift, accurate insights without invasive procedures. The team, led by Dr. Qinggong Tang, has adapted polarization-sensitive optical coherence tomography (PS-OCT)—an advanced imaging modality originally utilized in retinal scans—to noninvasively evaluate donor livers at high resolution.

Traditional liver assessments rely heavily on biopsies, where small tissue samples are extracted and examined for signs of disease or damage. While considered the gold standard, biopsies are inherently limited, providing only a microscopic snapshot of a vast organ that may vary in condition. This narrow sampling can cause uncertainty, sometimes leading to the discard of viable organs. The OU team sought to overcome these limitations by employing PS-OCT, which not only captures detailed cross-sectional images of liver tissue but also measures its polarization properties, revealing subtle structural and biochemical features linked to liver health.

The engineers designed a portable PS-OCT system optimized for clinical and operating room environments, allowing transplant teams to scan liver surfaces quickly and noninvasively. The imaging data are then analyzed using advanced artificial intelligence algorithms, co-developed with Dr. Chongle Pan’s computer science lab. These AI tools quantify critical parameters indicative of hepatic steatosis (fat accumulation) and inflammation, two primary factors influencing liver viability. By training their models on datasets from over thirty clinical cases—comparing PS-OCT results with biopsy outcomes and post-transplant organ function—the researchers demonstrated strong correlations between imaging biomarkers and actual clinical metrics.

Beyond providing a more holistic view of donor liver condition, PS-OCT could enhance decision-making speed, potentially expanding the pool of organs deemed suitable for transplantation by identifying healthy tissue regions missed by biopsy. Such improvements may reduce organ discard rates and improve transplant success. Encouraged by initial findings, the OU team plans a large multisite clinical trial involving institutions like UT Southwestern and the Cleveland Clinic to validate and refine this approach across diverse patient populations.

This work exemplifies OU’s interdisciplinary innovation platform that integrates optical bioimaging, machine learning, pathology, and organ perfusion technology to translate engineering advances directly into clinical practice. The researchers also intend to extend PS-OCT evaluation methods to other organs, including kidneys and lungs, widening the impact of this technology.

Supported by National Science Foundation grants and institutional partnerships, the team’s efforts mark a significant step toward redefining how transplanted organs are assessed. Dr. Tang emphasizes that this is just the beginning, envisioning a future where noninvasive, AI-enhanced imaging facilitates safer, faster, and more effective organ transplantation worldwide.

---

Subject of Research: Donor liver evaluation using advanced imaging techniques
Article Title: Human donor liver viability evaluation with polarization-sensitive optical coherence tomography
News Publication Date: 24-Jun-2026
Web References: http://dx.doi.org/10.1126/scitranslmed.adv7124
Image Credits: University of Oklahoma / Ellie Pinter

Keywords

Organ transplantation, Optical coherence tomography, Polarization-sensitive imaging, Liver viability, Artificial intelligence, Biomedical imaging, Noninvasive diagnostics, Medical innovation

Nearly half of American patients diagnosed with kidney failure face a significant hurdle that remains largely unnoticed: the daunting path from referral for kidney transplantation to actually being listed as a transplant candidate. A groundbreaking national study spearheaded by researchers from NYU Langone Health reveals that only about 19 percent of these patients complete the rigorous evaluation process required to join the kidney transplant waitlist. Alarmingly, nearly 48 percent never even commence this critical phase, underscoring a systemic challenge within transplant medicine that urgently warrants comprehensive attention.

Kidney transplantation is widely regarded as the optimal treatment for end-stage renal disease, significantly enhancing both survival rates and quality of life over long-term dialysis. Despite extensive research focusing on outcomes and management once patients are waitlisted or transplanted, the early stages—particularly the transition from referral to evaluation—have remained remarkably underexplored. The new study addresses this knowledge gap by meticulously analyzing data that track patient progression (or dropout) through each sequential step: referral, evaluation, waitlisting, and transplantation.

Leveraging the formidable Epic Cosmos database, which aggregates over 300 million electronic health records from more than 1,850 medical institutions—including over a third of all U.S. transplant centers—the research team was able to follow 720,348 adult patients referred for kidney transplantation between 2014 and 2025. By applying advanced statistical modeling, the researchers dissected how variables such as demographic factors, socioeconomic status, geographic location, and medical complexities influence patient trajectories through the transplant pipeline.

One of the study’s most compelling revelations is the multifaceted nature of barriers patients face long before they arrive on the transplant waitlist. Particularly vulnerable are unmarried individuals, those categorized with severe obesity, and patients residing in rural areas. These groups demonstrated disproportionately lower rates of starting and completing the transplant evaluation. The researchers suggest that limited social support, compounded by logistical challenges in accessing transplant centers mostly concentrated in urban settings, profoundly affects these disparities.

Language barriers and poverty add further layers of complexity. Older patients, Spanish speakers, and economically disadvantaged populations exhibited reduced odds of progressing beyond referral. The evaluation process itself, demanding repeated visits for comprehensive testing—including hematologic assays, radiologic imaging like chest X-rays, and oncologic screenings—can extend over months. This prolonged and intricate schedule poses significant strain on patients, particularly those simultaneously managing frequent dialysis treatments.

Institutional factors also shape patient outcomes. Smaller transplant centers, often with constrained resources and fewer transplant slots, tend to adopt more conservative patient selection criteria. This resource scarcity may lead to heightened risk aversion, amplifying the likelihood that individuals are filtered out early in the process. In contrast, larger centers with expansive infrastructure appear better suited to support patients through the complex evaluation stages, enhancing access equity.

Beyond healthcare infrastructure, psychosocial elements emerge as crucial determinants. The study highlights the importance of marital status and social support networks, which facilitate navigating the exhaustive appointment schedule and the psychological burden of chronic illness management. Candidates lacking robust social backings are more susceptible to discontinuing the transplant workup, emphasizing that transplant candidacy extends beyond physiological suitability to encompass holistic patient contexts.

The authors underscore that the transplant evaluation pathway remains one of the most intricate and strenuous journeys in medical care, entailing multifaceted specialist consultations, laboratory testing, and patient education. Each phase demands adequate patient understanding, resource availability, and logistical feasibility, accentuating the necessity for patient-centered strategies to democratize access.

Conor Donnelly, MD, the study’s lead author and PhD candidate at NYU Grossman School of Medicine, reflects on the striking influence of non-medical factors, stating the interplay of geography, healthcare center characteristics, and social environment decisively shapes transplant waitlisting outcomes. He advocates for system-level reforms targeting these upstream barriers to broaden equitable transplant access.

Allan B. Massie, PhD, co-senior author, emphasizes the potential impact of tailored educational efforts and patient navigation services to demystify and streamline the evaluation process. By reducing administrative burden and fostering comprehensible pathways, health systems can meaningfully increase the number of patients transitioning from referral to active waitlisting.

Similarly, Michal A. Mankowski, PhD, co-senior author and assistant professor of surgery, notes this study paves the way for probing analogous barriers in other organ transplant domains, each characterized by distinct logistical and clinical considerations. Expanding this research is vital for holistic transplant equity improvements.

The research, published June 20, 2026, in the Journal of the American Society of Nephrology and presented at the American Transplant Congress, marks the most extensive analysis to date of the attrition points in the kidney transplant continuum. These insights hold profound implications for policy frameworks, patient advocacy, and healthcare delivery models.

Addressing the entrenched social and systemic impediments to kidney transplantation demands coordinated efforts involving healthcare providers, payers, policymakers, and community stakeholders. Streamlining referral and evaluation protocols, augmenting support services, and ensuring resource availability at smaller centers—particularly in underserved regions—stand as imperatives.

NYU Langone Health’s funding and multidisciplinary team underscore the critical priority of tackling kidney transplant disparities with data-driven precision and commitment, aspiring to ensure that the lifesaving promise of transplantation reaches every eligible patient without undue delay or discrimination.

---

Subject of Research: People
Article Title: Evaluating Barriers to Kidney Transplantation in the United States
News Publication Date: 20-Jun-2026
Keywords: Organ transplantation, Renal failure, Nephropathies, Health care delivery, Health disparity, Health equity

La réputation de la courgette n'est plus à faire : c'est l'un des légumes les plus productifs du potager. À tel point que certains jardiniers ne savent plus comment les cuisiner là où d’autres se demandent pourquoi leurs plants restent chétifs… Si vous faites partie de ces malchanceux, bonne...